| Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma R Montal, D Sia, C Montironi, WQ Leow, R Esteban-Fabró, R Pinyol, ... Journal of hepatology 73 (2), 315-327, 2020 | 197 | 2020 |
| CXCR2 inhibition enables NASH-HCC immunotherapy J Leslie, JBG Mackey, T Jamieson, E Ramon-Gil, TM Drake, F Fercoq, ... Gut 71 (10), 2093-2106, 2022 | 78 | 2022 |
| Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials R Montal, C Andreu-Oller, L Bassaganyas, R Esteban-Fabró, S Moran, ... British journal of cancer 121 (4), 340-343, 2019 | 71 | 2019 |
| CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications S Franch-Expósito, L Bassaganyas, M Vila-Casadesús, ... elife 9, e50267, 2020 | 54 | 2020 |
| Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma L Bassaganyas, R Pinyol, R Esteban-Fabró, L Torrens, S Torrecilla, ... Clinical Cancer Research 26 (23), 6350-6361, 2020 | 42 | 2020 |
| Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma R Esteban-Fabró, CE Willoughby, M Piqué-Gili, C Montironi, ... Clinical Cancer Research 28 (11), 2449-2460, 2022 | 41 | 2022 |
| Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma R Esteban-Fabró, CE Willoughby, M Piqué-Gili, J Peix, C Montironi, ... Journal of Hepatology 73, S40, 2020 | 5 | 2020 |
| Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents L Torrens, M Puigvehí, M Torres-Martín, H Wang, M Maeda, PK Haber, ... Clinical Cancer Research 28 (20), 4509-4520, 2022 | 4 | 2022 |
| CNApp: a web-based tool for integrative analysis of genomic copy number alterations in cancer S Franch-Expósito, L Bassaganyas, M Vila-Casadesús, ... bioRxiv, 479667, 2018 | 2 | 2018 |
| PCIG: a web-based application to explore immune–genomics interactions across cancer types A Pedrola, S Franch-Expósito, S Lahoz, R Esteban-Fabró, R Dienstmann, ... Bioinformatics 38 (8), 2374-2376, 2022 | 1 | 2022 |
| Aneuploidy profiles in hepatocellular carcinoma and their impact on tumor progression and immune features R Esteban-Fabró, L Bassaganyas, S Torrecilla, A Moeini, ... Cancer Research 79 (13_Supplement), 3095-3095, 2019 | 1 | 2019 |
| PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, M Pique-Gili, R Esteban-Fabro, G Philips, R Pinyol, ... HEPATOLOGY 78, S1871-S1872, 2023 | | 2023 |
| Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures S Cappuyns, M Piqué-Gili, R Esteban-Fabró, G Philips, R Pinyol, ... Journal of Hepatology 78, S52-S53, 2023 | | 2023 |
| TRANSLATING SINGLE-CELL TO BULK RNA SEQUENCING DATA TO IDENTIFY RESPONDERS TO CHECKPOINT INHIBITION IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, R Esteban-Fabro, G Philips, V Vandecaveye, M Pique-Gili, ... Hepatology 76, S1275-S1276, 2022 | | 2022 |
| PMEPA1 has an oncogenic role in hepatocellular carcinoma in the context of TGFβ signaling: data from single cell RNAseq and transgenic models R Pinyol, C Andreu-Oller, M Piqué-Gili, R Esteban-Fabró, ... European Journal of Cancer 174, S120, 2022 | | 2022 |
| PMEPA1: an oncogene in hepatocellular carcinoma linked to TGF-beta signaling C Andreu-Oller, M Piqué-Gili, M Barcena-Varela, R Pinyol, ... Journal of Hepatology 77, S45-S46, 2022 | | 2022 |
| PMEPA1 is an oncogene linked to TGF-β signaling in hepatocellular carcinoma M Pique-Gili, C Andreu-Oller, R Pinyol, M Bárcena-Varela, ... Cancer Research 82 (12_Supplement), 840-840, 2022 | | 2022 |
| PCIG: a web-based application to explore immune–genomics interactions across cancer types A Pedrola Gómez, S Franch-Exposito, S Lahoz, R Esteban-Fabró, ... Oxford University Press, 2022 | | 2022 |
| CABOZANTINIB ENHANCES THE EFFICACY AND IMMUNE MODULATORY ACTIVITY OF ANTI-PD1 TREATMENT IN A SYNGENEIC MOUSE MODEL OF HCC R Esteban-Fabro, CE Willoughby, M Pique-Gili, J Peix, J Abril-Fornaguera, ... HEPATOLOGY 70, 1201A-1202A, 2019 | | 2019 |
| PS-048-Definition of aneuploidy profiles and their impact on tumour progression and immune features in hepatocellular carcinoma R Esteban-Fabro, L Bassaganyas, S Torrecilla, A Moeini, ... Journal of Hepatology 70 (1), e30, 2019 | | 2019 |
